GSK will invest £400m in a new flagship research and development centre on the Cambridge Biomedical Campus, the company announced on 28 July 2026 alongside its first-half results. The 300,000-square-foot facility will house more than 1,000 scientists and is slated for completion within three years, with the investment spread across that period (Reuters; GSK press release).

The historic Stevenage site will close, with most scientists relocating to Cambridge. GSK's global headquarters remains in London, separate from the new R&D centre (Reuters).

The Cambridge investment arrived bundled with harder numbers. GSK unveiled a plan to cut £1.9bn in annual costs by 2029 and said it intends to put at least 20 potential medicines into late-stage trials in 2026, double the 10 it had previously targeted. The company also confirmed a revenue target of £40bn-plus (The Guardian).

Luke Miels, who took over as chief executive at the start of 2026, is presiding over this strategic realignment. In approximately June 2026, GSK completed the acquisition of US-based cancer specialist Nuvalent for nearly £8bn, deepening its oncology pipeline (The Guardian).

The urgency behind the R&D expansion and cost-cutting programme stems in part from GSK's HIV franchise. Dolutegravir, the company's anchor HIV medicine, accounts for about one-fifth of group sales. Patents on the drug expire between 2028 and 2030. GSK has predicted its operating profit margins will be "stable to improving" during that patent cliff period (The Guardian).

GSK already invests over £6bn in R&D annually, making the £400m Cambridge commitment a targeted geographic and strategic consolidation rather than a net increase in research spending (Reuters).

The Cambridge Biomedical Campus is already home to major research institutions, giving GSK proximity to academic and clinical collaborators. The decision to concentrate research talent there, while shuttering Stevenage, signals a bet that density of scientific expertise matters more than dispersed facilities. Whether 1,000-plus scientists can be moved or recruited without disruption is an operational question the company will face over the three-year build.

The broader context here is that the cost-cutting target of £1.9bn by 2029 and the R&D consolidation are likely linked. Concentrating scientists in one location rather than maintaining separate sites is a standard lever for reducing overhead — the ongoing costs of running facilities, equipment, and support staff. The doubling of late-stage trial candidates, meanwhile, puts pressure on GSK's development and regulatory teams, since each Phase III programme (the final, large-scale testing stage before a drug can be submitted for approval) carries substantial cost and execution risk.

The dolutegravir patent expiration timeline is the structural pressure underpinning all of this. A patent cliff — the period when exclusive patents expire and cheaper generic competitors can enter the market — means losing exclusivity on a drug that generates roughly 20% of group revenue creates a revenue gap that new products must fill. GSK's assertion that margins will hold through that period depends on its pipeline delivering commercially viable replacements, which is precisely what the expanded late-stage programme is designed to produce.

The Guardian's Nils Pratley, whose analysis column on the Cambridge investment was published on 28 July 2026, framed the announcement as delivering long-awaited positive momentum for the company (The Guardian).